Ticagrelor hemorrhagic safety in patients with acute coronary syndrome with ST-segment elevation received thrombolytic therapy in daily clinical practice: 30-day observation results

Background. Effective antithrombotic therapy is a necessary condition for maintaining the patency of the infarct-dependent coronary artery during a primary percutaneous coronary intervention. Aim. To compare the safety of ticagrelor use in patients with STEMI after ineffective thrombolytic treatment (TLT) and successfully performed recanalization of infarct-dependent artery (IDA) by PCI, withticagrelor loading dose administered in the time window from TLT to PCI, in comparison with the TREAT study results on the risk of bleeding in the real clinical practice. Methods. A comparative analysis of the results of a 30-day follow-up of 52 patients with acute coronary syndrome with ST-segment elevation who received a thrombolytic therapy with alteplasa and early ticagrelor administration with the ticagrelor group in the TREAT study on the parameters of hemorrhagic safety. Results. Arterial hypertension, dyslipidemia, generalized atherosclerosis, chronic obstructive pulmonary disease and a history of myocardial infarction were significantly more common in the study group...